CNW/ - Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by public drug programs in Ontario, ...
10h
Libtayo® (cemiplimab for injection) Now Reimbursed in Québec for Advanced Non-Small Cell Lung Cancer
CNW/ - Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by Régie de l'assurance maladie du ...
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
Q3 2025 Earnings Call Transcript October 28, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS ...
Biotech company Regeneron (NASDAQ:REGN) reported Q3 CY2025 results exceeding the market’s revenue expectations, but sales were flat year on year at $3.75 billion. Its non-GAAP profit of $11.83 per ...
The chipmaker at the heart of the AI boom was one of the top performers in the S&P 500 Tuesday, helping push the index to an ...
2don MSN
Regeneron targets $7B in U.S. manufacturing investment as R&D and commercial launches accelerate
Q3 2025 Management View CEO Leonard Schleifer reported "double-digit net sales growth for 3 of our leading products," ...
Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...
Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, but sales were ...
Return on Assets (ROA): Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.67%, the company showcases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback